The methods available to monitor and control a defined depth of anaesthesia are imprecise and controversial. Clinical signs dependent on the loss of specific reflexes and changes in the autonomic nervous system have been used since the advent of anaesthesia (Robson, 1969) . Although these changes have been found to be fairly consistent with some of the commonly used inhalation anaesthetic agents, the i.v. agents do not demonstrate a predictable association between depth of anaesthesia and clinical signs. The use of neuromuscular blocking agents further interferes with a reliable assessment of depth of anaesthesia. Therefore, it may prove difficult during total i.v. anaesthesia to maintain a careful balance between too light a level of anaesthesia and possible awareness, and too deep a level with, consequently, a more prolonged recovery of consciousness.
Cerebral depression, whether by drugs or other causes is associated with characteristic changes in cerebral electrical activity (Stockard and Bickford, 1975; Marshall, Longley and Stanton, 1965) . The electroencephalogram (e.e.g.) has demonstrated similar changes of cerebral electrical patterns in association with increasing depth of anaesthesia during the administration of different anaesthetic agents (Martin, Faulconer and Bickford, 1959; Sadove, Becka and Gibbs, 1967; Scott and Virden, 1972) . Distinctive e.e.g. patterns were described by Prior, Maynard and Brierly (1978) at six clinically defined levels of anaesthesia following different rates of infusion of Althesin in primates, and they demonstrated that each e.e.g. pattern had an equivalent CFM signal. Dubois and colleagues (1978) reported the use of the CFM to monitor depth of anaesthesia in man. This was further investigated in a preliminary study which related the plasma concentrations of alphaxalone with the CFM signal during minimal anaesthesia produced by a continuous infusion of Althesin (Savege, Zych and Dubois, 1978) .
In the present investigation regular, repeated bolus doses of i.v. anaesthetic agents were administered to provide a rapidly changing pharmacokinetic situation which could be used to test further the relationship between the CFM signal and plasma concentrations of anaesthetic agents.
PATIENTS AND METHODS
Ten healthy patients who had given their informed consent and were undergoing general or gynaecological surgery of moderate duration were included in the study.
Patients were premedicated with papaveretum and hyoscine as experience from preliminary work had shown that unpremedicated patients tended to move during the procedure and the consequent © The Macmillan Pres* Ltd 1982 disturbance of the electrodes produced artefactual voltages on the CFM. Patients were brought to the anaesthetic room 40min before the operation was due to start. Biparietal silver/silver chloride electrodes were placed 5 cm apart on either side of the midline, and attached to the CFM (Ormed Ltd) and an awake trace was obtained. Anaesthesia was induced with thiopentone 5mgkg-' or Althesin 50^1 kg" 1 , administered over 20 s with a syringe infusion pump. Increments of half the induction dose were injected over 10 s every 240 s following induction. The patients breathed oxygen through a mask and their arterial pressure and heart rate were monitored.
Blood samples for the estimations of drug concentration were taken through a wide-bore indwelling cannula in an antecubital vein of the arm opposite to that used for the injection. Two sets of samples were obtained: one at 60 s after each increment when anaesthesia was judged to be at or near maximum depth; the second at 225s, that is 15s before the next bolus, to coincide with the point of maximum recovery from anaesthesia. Three patients also had blood samples collected at 30 s after each bolus. The time and duration of each injection and blood sampling were recorded using the CFM event marker.
Thiopentone concentrations in plasma were determined by gas chromatography based on the micro-method of Flanagan and Withers (1972) and utilizing the nitrogen detector (Breiner and Van Rossum, 1974) . The barbiturate was extracted from plasma with chloroform, which was then removed and evaporated to dryness, and the residue redissolved in acetone of which 2 jilitre was injected onto the column. Separation was achieved on a Perkin Elmer Sigma 2 gas chromatograph containing a 2-m glass column packed with GP 3% SP2250 DA on Supelcoport 100-120 mesh (Chromatography Services Ltd) and a carrier gas of nitrogen. Each sample and standard contained an internal standard of propylphenazone which passed through the whole extraction procedure. Plasma alphaxalone concentrations were estimated by a gas chromatographic method. The alphaxalone was extracted from plasma with ether, and a heptafluorobutyrate derivative formed to facilitate separation from endogenous compounds and quantitation by electron capture detection (Exley and Chamberlain, 1967) . Separation was performed by gas chromatography on a 2-m column of 5% SE30 coated Gas-Chrom Q. Recovery of alphaxalone throughout the procedure was corrected for by inclusion of an internal standard, 3 p'-alphaxalone.
The means of the heights of the upper and lower edges of the CFM trace over the duration of each sampling period were calculated. Correlations between plasma drug concentrations and the upper and lower edges of the CFM trace were calculated using the Statistical Package for Social Sciences, and the significance of the correlations were obtained using Thiopentone. A typical trace obtained with thiopentone ( fig. 1 ) consisted of an initial steep rise from the resting awake trace to a peak within 20-30 s from the beginning of the injection. Usually a second smaller peak occurred after the second bolus of thiopentone. Subsequently, each bolus dose was followed by a gradual depression of the trace. After the fifth injection a more definite and pronounced depression towards the baseline occurred. At this stage, the trace was much broader, ranging from a lower edge of 1-2 nV to an upper edge of 20-25 jiV. After the sixth injection, the trace fell abruptly towards the baseline where it remained for 10-12 s before becoming broad again and then rising and narrowing.
When the traces of all the patients who received thiopentone are examined, a similarity in principle of the changes described is evident ( fig. 2 ).
Althesin. The traces obtained from patients receiving Althesin showed a different pattern ( fig. 1 ). The descent from the initial peak following induction was steeper, and was followed by a further marked depression after the second injection. Subsequently, a marked and progressive stepwise descent and broadening of the trace occured after each successive bolus, followed each time by a rise and narrowing of the trace which became less marked as doses accumulated. These changes were generally consistent in all the traces of patients who received Althesin ( fig. 3) . In figures 4 and 5 (thiopentone and Althesin respectively) the parallel relationships between the CFM and plasma drug concentrations are shown. However, for thiopentone, the first two repeat boluses were followed by further "peaks" after each injection and the opposite relationship between CFM and plasma thiopentone concentration is evident over this period. In table I the correlations between plasma thiopentone or alphaxalone concentrations and the upper and lower edges of the CFM are noted respectively for each patient. (Those measurements following the initial bolus or preceding a second CFM peak after further boluses were excluded.) It is evident that, in general, the lower edge CFM measurements gave a better correlation (r = -0.75 to r = -0.95) than the upper edge A parallel trend is evident after the third increment. After the first and second increment, the CFM trace is associated with recovery from, rather than deepening of anaesthesia, as confirmed by the smaller peaks seen after these increments, representing "reinduction" of anaesthesia.
(r= -0.56 to r= -0.91). All correlations are highly significant (P<0.02 on all occasions). In some patients, for instance patient No. 6 in table I, the correlation and its significance improved markedly when the relationships at 60s after the bolus and those at 225 s were calculated separately. This is shown graphically in figures 6 and 7 where the plasma thiopentone or alphaxalone concentrations at 60 ("post-incremental") and 225 s ("preincremental") have been plotted separately against the upper and lower edges of the CFM for patients Nos 6 and 4 respectively.
The measurements of the plasma drug concentrations for each patient are plotted against the corresponding CFM values in figure 8 . Each line represents the best fit curve by the least square error method for the data obtained from one patient. Although some individual variation is evident, it is notable that there is a clear tendency for the slopes for each drug, and for the upper or lower CFM edges, to cluster together. Three patients who received thiopentone had blood samples taken at 30 s after each bolus injection as well as at 60 and 225 s. There was no correlation between plasma thiopentone concentrations and the CFM trace at 30 s. The plasma thiopentone concentrations of patient No. 10 are shown in figure 9 . The 30-s post-incremental plasma concentration was found to rest either on a high peak, or (on two occasions) along the line of the values at 225 s (i.e. "pre-incremental"), while those at 60 and at 225 s showed a consistent trend.
DISCUSSION
The CFM displays cerebral electrical activity as a filtered, integrated and compressed signal. The height of the write-out represents total microvoltage in a semilogarithmic scale, that is the scale is linear up to 12-15nV, above this value it becomes logarithmic; this exaggerates the changes which take place at low amplitudes when cerebral depression becomes marked. The breadth of the trace corresponds to the difference between maximum and minimum voltages in unit time, that is the variability of cerebral electrical activity.
In anaesthesia, a typical pattern emerges. Following induction, the initial peak from the resting awake trace is consistent with the increased cerebral activity that is associated with induction and light levels of anaesthesia. The descent of the trace following this initial peak is the only ambiguous sign, as it may represent either a deepening of the level of anaesthesia as cerebral activity becomes slower and more depressed, or a lightening of anaesthesia back towards the awake trace. If the latter occurs, the next dose of the drug would be expected to induce another peak of cerebral activity which appears to correspond to reinduction of anaesthesia. This was shown when bolus doses of thiopentone were administered, suggesting a rapid recovery from anaesthesia following the first and sometimes the second injection. In figure 4 the first two boluses after induction were associated with "reinduction" peaks, and the CFM had a reverse relationship to plasma concentrations of thiopentone over this period. The CFM trace obtained with Althesin, in contrast, consistently showed a steep descent, suggesting deepening of anaesthesia following each bolus injection. The subsequent lowering and broadening of the trace, as additional injections of i.v. anaesthetic agent are given, are consistent with further depression of cerebral activity as the drug begins to cumulate and anaesthesia deepens. This is confirmed in figure 5 , where a parallel relationship between plasma alphaxalone concentration and CFM is evident from the first bolus on. The alternation between periods of cerebral electrical silence and bursts of activity, that is the e.e.g. "burst suppression" associated with the deeper levels of anaesthesia, is demonstrated in the CFM as a broad band with its lower edge close to the baseline or near electrical silence, and the upper edge representing electrical bursts of activity. The CFM of patients who received thiopentone showed an abrupt onset of burst suppression, usually after the fifth or sixth dose. The CFM of patients receiving Althesin, in contrast, showed a regular and steady increase in depth of anaesthesia, and presumably, cumulation of the drug.
The preceding description of the CFM output in anaesthesia is in accordance with known changes in cerebral electrical activity during anaesthesia, and the corresponding modification of the signal by the CFM. In the present investigation, the changes in the CFM output during i.v. anaesthesia were further evaluated by comparing them with plasma concentrations of thiopentone or alphaxalone. Plasma concentrations of anaesthetic agents, by virtue of the rapid equilibrium reached with brain concentrations, have been used as a criterion of depth of anaesthesia. However, changing pharmacokinetic and phannacodynamic effects, variable time lags and other circulatory factors relating to the site of blood sampling, are likely to make plasma drug concentration an insensitive indicator of concurrent cerebral depression.
In some previous studies, a high correlation was found between plasma concentrations of thiopentone and the corresponding brain concentrations or function (Mark et al., 1957; Goldstein and Aronow, 1960; Becker, 1978) . However, a lack of correlation between plasma concentrations of thiopentone and cerebral activity or responsiveness was demonstrated by Brand and colleagues (1961) and Dundee and co-workers (1979) . These workers suggested the development of acute tolerance as an explanation. In the studies referred to, blood samples for thiopentone estimations were collected from various sites, which included arterial, central venous and peripheral venous.
For the patients used in the present study it was considered unjustifiable to introduce a central venous line, consequently blood was collected from the antecubital vein. The uptake of thiopentone by the tissues in the hand and forearm is not expected to be as avid as that of the brain, and it is likely that this sampling site would give concentrations closer to arterial values (R. E. Bullingham, 1980, personal communication) than those found in blood from the internal jugular vein, where Price (1961) demonstrated that thiopentone concentrations do not reach the initial high peak found in arterial blood. The peripheral venous plasma concentrations shown in figure 9 tend to confirm this. In a recent unpublished study Major, Savege and Verniquet found that plasma diisopropyl-phenol concentrations measured simultaneously in arterial, peripheral venous, and central venous blood, following an initial bolus injection in four patients, showed a changing relationship over the first 60 s following the end of the injected bolus. However, the arterial, peripheral and central venous concentrations of diisopropylphenol became identical within a narrow margin of experimental error, after 60 s.
In the present investigation, there was no correlation between the CFM signal and plasma thiopentone concentrations at 30 s following an i.v. bolus injection. It is possible that, at this interval, the circulating bolus has not yet mixed thoroughly in the circulation ( fig. 9 ). However, plasma thiopentone or alphaxalone estimations at 60 s or later following a bolus, correlated well with the CFM. In the rapidly changing pharmacokinetic situation it was found that the best correlations occurred when the drug concentrations were compared with the CFM at a single point in the 240 s cycle (that is at 60 or at 225 s).
The results of this study indicate that the CFM may provide a direct and reliable measure of anaesthetic depth when using i.v. anaesthetic agents. This is relevant at a time when there is interest in total i.v. anaesthesia as a means of avoiding theatre pollution by inhalation anaesthetic gases, and also to provide a more selective control of "balanced anaesthesia". The quantification of cerebral depression by the CFM may also be used to study the behaviour of i.v. anaesthetic agents. In this study the examination and comparison of traces obtained following the incremental administration of thiopentone or Althesin demonstrated differences in the rate and onset of cumulation and in anaesthetic recovery between these two anaesthetic agents. It is suggested that the inter-drug CFM differences noted reflect differences in their relative potencies and in their pharmacokinetics. 
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